We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Addition of Teicoplanin or Vancomycin for the Treatment of Documented Bacteremia due to Gram-Positive Cocci in Neutropenic Patients with Hematological Malignancies: Microbiological, Clinical and Economic Evaluation.
- Authors
D. DAntonio; T. Staniscia; R. Piccolomini; G. Fioritoni; S. Rotolo; G. Parruti; G. Di Bonaventura; A. Manna; V. Savini; M.P. Fiorilli; P. Di Giovanni; A. Francione; F. Schioppa; F. Romano
- Abstract
A prospective, randomized, double-blind trial was conducted on 124 febrile patients with hematological malignancies to compare teicoplanin with vancomycin as an addition to the initial empiric amikacin-ceftazidime regimen after documented bacteremia due to gram-positive cocci. At enrolment, patients in both groups were comparable with respect to age, sex, underlying hematologic disorders and duration of neutropenia. Rates of therapeutic success were 55/63 (87.3%) in the teicoplanin group and 56/61 (91.8%) in the vancomycin group (p = 0.560). The mean duration of treatment was similar, being 12.2 and 11.4 days, respectively (p = 0.216). Patients treated with teicoplanin remained febrile for slightly longer than those treated with vancomycin (4.9 vs. 4.0 days) (p = 0.013). Thirteen patients experienced an adverse drug reaction, but without any significant difference in the two arms. Isolated staphylococci showed a progressive and significant decrease in susceptibility to both glycopeptides during the 8 study years. The economic analysis performed showed that the addition of vancomycin is cost-saving.Copyright © 2004 S. Karger AG, Basel
- Subjects
VANCOMYCIN; ANTIBACTERIAL agents; NEUTROPENIA; BACTEREMIA; HEMATOLOGY; GLYCOPEPTIDES
- Publication
Chemotherapy (0009-3157), 2004, Vol 50, Issue 2, p81
- ISSN
0009-3157
- Publication type
Article